Page 1244 - Small Animal Clinical Nutrition 5th Edition

1296 SMALL ANIMAL CLINICAL NUTRITION

C key nutritional factors, 676
Cachexia, 148c, 441, 442 risk factors for, 673
cancer, 588-591, 589t, 591f Canine calcium oxalate urolithiasis, 855-870
VetBooks.ir Calcitonin, 112-113, 113f, 670, 673, 676 calcium- and oxalate-rich foods to avoid, 858t
cardiac, 735, 742-743, 743f
common characteristics of, 857t
Calcitriol, use in renal failure, 770, 772, 777f, 780t, 782t, 794 dietary risk factors, 856-857
Calcium, 108t, 112-114 etiopathogenesis of, 856-861
homeostasis of, 112, 113f expected changes during medical therapy, 865t
recommendations in FLUTD, 937, 946t, 948-949, 949t feeding plan and treatment for, 863-868
relationship to dental disease, 991 foods with minimal calcium and oxalate content, 862t
relationship to developmental orthopedic disease in dogs, key nutritional factors, 861-863, 861t
671-673, 675-676, 678-679, 679b managing recurrent cases of, 866t
requirements/deficiencies/excesses, 113, 114b prevalence and mineral composition of, 855-856
requirement/recommendation reassessment of, 868
of growing cats, 430t recurrence rates of, 861
of growing dogs, 312t risk factors for, 856-861
of mature adult cats, 393-394, 396t Canine calcium phosphate urolithiasis, 871-880
of mature adult dogs, 277 common characteristics of, 872t
of nursing kittens, 421 distal renal tubular acidosis, 873t, 874-875
of nursing puppies, 303, 303t etiopathogenesis of, 872-875
of reproducing cats, 406, 409t feeding plan and treatment for, 877-879
of reproducing dogs, 287t, 288 foods for prevention, 879t
of young adult cats, 376t, 383-384 key nutritional factors, 875-877, 876t
Calcium carbonate, 216, 407b, 816b, 871 predisposing disorders for, 873-875
Calcium oxalate urolithiasis prevalence and mineral composition of, 871-872
in cats, 941-943 primary hyperparathyroidism, 873-874
calcium-rich foods to avoid, 949t reassessment of, 879-880
in dogs, (See Canine calcium oxalate urolithiasis) risk factors for, 872-875
Calcium phosphate urolithiasis, in dogs (See Canine calcium Canine compound urolithiasis, 921-923, 922-923c
phosphate urolithiasis) Canine cystine urolithiasis, 881-890
Calcium-phosphorus ratios, 114b, 213, 287t, 288-289, 303, etiopathogenesis of and risk factors for, 882-883
314, 344b, 383-384, 394, 406, 419, 421, 431, 468, 678-679, expected changes during medical therapy, 885t
682, 682t, 862, 865t, 876, 876t, 917, 1260, 1260t feeding plan and treatment for, 886-888
Calculations foods for dissolution and prevention, 883
as fed to dry matter basis, 11b key nutritional factors for, 885-886
energy requirement, 15b managing refractory cases of, 886t
same energy density, 12b mineral composition, 882
Calculolytic foods (See Litholytic foods) prevalence, 881-882
Calculus (dental), 39, 166t, 176t, 390t, 397, 677, 981-982, prevention of, 888
984, 986-988, 986f, 987b,, 988f, 990f, 993, 993f, 994, 996c thiol-containing drugs for management of, 887
Cancer, 585-607 Canine purine urolithiasis, 833-853
amino acids and, 598b adjunctive medical/surgical management 843-845
assessment of animals with, 588-597 common characteristics of, 824t
cachexia, 590-591, 591f dietary risk factors, 835t, 838
carbohydrate metabolism in patients with, 593-595 etiopathogenesis of, 834-838
clinical importance of, 587-588 expected changes during medical therapy, 845t
clinical/metabolic phases of, 589t feeding plan, 840-842
commercial foods for cancer patients, 600t foods for dissolution and prevention, 841t
energy requirement for patients with, 601 key nutritional factors, 839-840, 839t
etiopathogenesis, 590 managing immature dogs with urate uroliths, 843b
feeding plan for, 598-603 managing refractory cases of, 846t
key nutritional factors for, 593-597 prevalence and mineral composition, 833-834
lipid metabolism in patients with, 590, 593, 595 prevention of, 846-847
metabolic alterations in patients with, 588, 590 purine content of selected foods, 836t
minerals and, 599b reassessment of, 845-846
nutritional effects of cancer treatment, 591-593 risk factors for, 835t
nutritional effects of cancer, 587-588 summary for medical dissolution and prevention of, 841t
protein metabolism in patients with, 593, 596-597 Canine silica urolithiasis, 915-920
risk factors, 589-590 adjunctive medical management, 919-920
vitamins and, 599b commercial foods for prevention of, 919t
Canine hip dysplasia, 312, 315, 334, 667-668, 668f, 672t, etiopathogenesis of and risk factors for, 916-918
686c, 697, 707 feeding plan and treatment for, 918-919